Teva Pharmaceutical Industries (TEVA) Leases (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Leases for 9 consecutive years, with $335.0 million the latest figure, recorded in Q1 2026.

• Quarterly Leases fell 7.71% year-over-year to $335.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335.0 million (down 7.71% YoY) and the FY2025 annual result came in at $345.0 million, down 5.99% from the prior year.
• Leases eased to $335.0 million in Q1 2026 per TEVA's latest filing, from $345.0 million in the prior quarter.
• Over the last five years, Leases for TEVA reached as high as $464.0 million in Q1 2022 and fell as low as $335.0 million in Q1 2026.
• A 5-year average of $387.2 million and a median of $367.0 million in 2024 frame the typical range for Leases.
• Annual changes were most pronounced in 2022 — Leases fell 16.95% — and 2025, when it changed 0.0%.
• Year by year, Leases stood at $419.0 million in 2022, then slipped by 5.25% to $397.0 million in 2023, then retreated by 7.56% to $367.0 million in 2024, then declined by 5.99% to $345.0 million in 2025, then retreated by 2.9% to $335.0 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $335.0 million, $345.0 million, and $342.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.